Changes

1,086 bytes added ,  21:53, August 28, 2025
As of August 28, 2025, Arkansas, Idaho, Louisiana, and Tennessee have all enacted legislation that makes ivermectin available without a prescription ("over the counter"), and Texas has pending legislation to do likewise.
Line 1: Line 1: −
'''Ivermectin''' is an off-[[patent]] (generic), inexpensive medication which was originally produced by Merck & Co., Inc. It has also been known by various trade names, including Stromectol and Sklice. It was made commercially available in 1981, and has been widely used since then for a variety of parasitic infections, as well as a few anti-viral applications. The patent for this self-proclaimed "wonder drug" expired in 1996, and it is now available from over a dozen generic manufacturers, for around $0.40 per dose (as of 2022). Due to its significant safety and effectiveness, it was added to the World Health Organization's List of Essential Medicines. Prior to the COVID-19 pandemic, about 30% of prescriptions in the United States for Ivermectin were for "off-label" use.<ref name="The real Anthony Fauci">Kennedy, R. F. (2022). Chapter 8. The real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health. essay, Skyhorse Publishing.</ref>  
+
'''Ivermectin''' is an off-[[patent]] (generic), inexpensive medication which was originally produced by [[Merck]]. It has also been known by various trade names, including Stromectol and Sklice. It was made commercially available in 1981, and has been widely used since then for a variety of parasitic infections, as well as a few anti-viral applications. The patent for this self-proclaimed "wonder drug" expired in 1996, and it is now available from over a dozen generic manufacturers, for around $0.40 per dose (as of 2022). '''''[[Big Pharma]] opposes ivermectin because it cuts into their profits on [[vaccine]]s and patented drugs'''''.
−
It is also widely considered to be an effective treatment for [[COVID-19]] as suggested by numerous, constantly updated studies compiled online and by peer-reviewed studies worldwide.<ref>https://ivmmeta.com/</ref>  The Chairman of the [[Japan]]ese medical association announced in late August 2021 that physicians should use Ivermectin to treat COVID-19, but it continues to be suppressed by [[liberal]]s in the [[United States]].  "A 5-day course of Ivermectin was found to be safe and effective in treating adult patients with mild COVID-19," according to a study published in a journal posted by the [[NIH]]'s National Library of Medicine.<ref>https://pubmed.ncbi.nlm.nih.gov/33278625/</ref>  Its beneficial biological mechanism has been published by an NIH peer-reviewed article.<ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996102/</ref>
+
 
 +
As of August 28, 2025, Arkansas, Idaho, Louisiana, and Tennessee have all enacted legislation that makes ivermectin available without a prescription ("over the counter"), and Texas has pending legislation to do likewise. Yet some pharmacy chains may refuse to carry it, and independent pharmacies are more likely to.
 +
 
 +
Due to its significant safety and effectiveness, it was added to the World Health Organization's List of Essential Medicines. Prior to the COVID-19 pandemic, about 30% of prescriptions in the United States for Ivermectin were for "off-label" use.<ref name="The real Anthony Fauci">Kennedy, R. F. (2022). Chapter 8. The real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health. essay, Skyhorse Publishing.</ref>  
 +
It is also widely considered to be an effective treatment for [[COVID-19]] as suggested by numerous, constantly updated studies compiled online and by peer-reviewed studies worldwide.<ref>https://ivmmeta.com/</ref>  The Chairman of the [[Japan]]ese medical association announced in late August 2021 that physicians should use Ivermectin to treat COVID-19, but it was continuously suppressed by [[liberal]]s in the [[United States]].  "A 5-day course of Ivermectin was found to be safe and effective in treating adult patients with mild COVID-19," according to a study published in a journal posted by the [[NIH]]'s National Library of Medicine.<ref>https://pubmed.ncbi.nlm.nih.gov/33278625/</ref>  Its beneficial biological mechanism has been published by an NIH peer-reviewed article.<ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996102/</ref>
    
Litigation by [[Judicial Watch]] uncovered that [[British]] physicians scientists recommended ivermectin to treat and prevent [[COVID-19]],<ref>https://www.judicialwatch.org/ivermectin-for-treatment-of-covid/</ref> yet this was withheld from the public during the pandemic.
 
Litigation by [[Judicial Watch]] uncovered that [[British]] physicians scientists recommended ivermectin to treat and prevent [[COVID-19]],<ref>https://www.judicialwatch.org/ivermectin-for-treatment-of-covid/</ref> yet this was withheld from the public during the pandemic.
Line 34: Line 38:     
==Competing COVID-19 treatments==
 
==Competing COVID-19 treatments==
−
Due to Ivermectin being out of patent, there is very little profit in selling it as a treatment. However, in December 2020 Merck signed a $356 million dollar supply deal with NIAID. They would supply 60,000-100,000 doses of a new experimental COVID-19 treatment pill called "MK-7110" (formerly known as "CD24Fc"). OncoImmune originally created the drug, but Merck bought out that company for $425,000,000, acquiring rights to the drug. [[Bill Gates]]' International Aids Vaccine Initiative agreed to distribute this new drug throughout developing nations. The undertaking was later discontinued.<ref name="The real Anthony Fauci">Kennedy, R. F. (2022). Chapter 8. The real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health. essay, Skyhorse Publishing.</ref> <ref>https://www.merck.com/news/merck-to-discontinue-development-of-mk-7110-for-covid-19/</ref>
+
Due to Ivermectin being out of patent, there is very little profit in selling it as a treatment. However, in December 2020 Merck signed a $356 million dollar supply deal for an alternative option, with NIAID. They would supply 60,000-100,000 doses of a new experimental COVID-19 treatment pill called "MK-7110" (formerly known as "CD24Fc"). OncoImmune originally created the drug, but Merck bought out that company for $425,000,000. [[Bill Gates]]' International Aids Vaccine Initiative agreed to distribute this new drug throughout developing nations. However, the entire undertaking was later discontinued.<ref name="The real Anthony Fauci">Kennedy, R. F. (2022). Chapter 8. The real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health. essay, Skyhorse Publishing.</ref> <ref>https://www.merck.com/news/merck-to-discontinue-development-of-mk-7110-for-covid-19/</ref>
 +
 
 +
Merck also hoped to make massive profit from another new drug they were working on, Molnupiravir. This was a newly developed protease inhibitor, which utilizes a mechanism identical to that of Ivermectin to stop viruses, but as a new drug, could be patented. The Defense Threat Reduction Agency provided $10,000,000 in 2013 and 2015 to Emory University, to develop Molnupiravir as a veterinary drug for horses, to treat equine encephalitis. NIAID contributed $19,000,000, and then handed off the drug to Merck and Miami-based Ridgeback Biotherapeutics. They immediately set to work getting ready to sell the new drug as a COVID-19 treatment, worth billions of dollars. It was slated to sell for $700 per treatment course. However, there were major safety concerns, even among some of its co-developers at Emory University. There were fears that Molnupiravir would cause serious side affects, including birth defects. It is sold under the brand name "Lagevrio."<ref name="The real Anthony Fauci">Kennedy, R. F. (2022). Chapter 8. The real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health. essay, Skyhorse Publishing.</ref>
   −
Merck also hoped to make massive profit from another new drug they were working on, Molnupiravir. This was a newly developed protease inhibitor, which utilizes an identical mechanism to stop viruses, but as a new drug, could be patented. The Defense Threat Reduction Agency provided $10,000,000 in 2013 and 2015 to Emory University, to develop Molnupiravir as a veterinary drug for horses, to treat equine encephalitis. NIAID contributed $19,000,000, and then handed off the drug to Merck and Miami-based Ridgeback Biotherapeutics. They immediately set to work getting ready to sell the new drug as a COVID-19 treatment, worth billions of dollars. It was slated to sell for $700 per treatment course. However, there were major safety concerns, even among some of its co-developers at Emory University. There were fears that Molnupiravir would cause serious side affects, including birth defects. It is sold under the brand name "Lagevrio." <ref name="The real Anthony Fauci">Kennedy, R. F. (2022). Chapter 8. The real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health. essay, Skyhorse Publishing.</ref>
+
As Merck was working on their Ivermectin knock-off, Pfizer also joined the race with their own protease inhibitor, "PF-07321332" (Nirmatrelvir). This drug was also very similar in mechanism and function to Ivermectin, to the extent that it was given the nickname "Pfizermectin." Like Molnupiravir, this drug was designed to be a patent-protected replacement for Ivermectin, so price gouging would be possible.<ref name="The real Anthony Fauci">Kennedy, R. F. (2022). Chapter 8. The real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health. essay, Skyhorse Publishing.</ref>
   −
Experimental vaccines were also a major competitor to Ivermectin. Multiple pharmaceutical companies were seeking emergency approval for their new products, but that can only be granted if there are no pre-existing treatments which are effective and approved as safe. It was therefore of utmost importance that any other pre-existing medication be found ineffective, so their emergency use of the vaccines could be approved.
+
Experimental vaccines were also a major competitor to Ivermectin. Multiple pharmaceutical companies were seeking emergency approval for their new products, but that can only be granted if there are no pre-existing treatments which are effective and approved as safe. It was therefore of utmost importance that any other pre-existing medication be found ineffective, so their emergency use of the experimental vaccines could be approved.
    
== See also ==
 
== See also ==
Anthony, Irenaeus, Siteadmin, apieditor, Bureaucrats, Check users, nsAm_Govt_101RO, nsAm_Govt_101RW, nsAm_Govt_101_ta, nsJudgesRO, nsJudgesRW, nsJudges_talkRO, nsJudges_talkRW, nsTeam2RO, nsTeam2RW, nsTeam2_talkRO, nsTeam2_talkRW, oversight, Administrators
126,424

edits